Aprea director granted RSUs and stock options
Aprea Therapeutics director Rifat Pamukcu reported new equity awards and updated holdings.
Rhea-AI Filing Summary
Aprea Therapeutics director Rifat Pamukcu reported new equity awards and updated holdings. On June 16, 2026, he received 3,135 restricted stock units that will vest and settle in common stock on June 16, 2027, subject to his continued board service and possible acceleration under certain conditions.
He was also granted stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, vesting in full on June 16, 2027 under similar service-based conditions. Following these awards, he directly holds 8,581 common shares and 12,555 options, and indirectly holds 14,108 common shares through ZNZ Holdings LLC, where he serves as Manager Partner.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 15,690 shares
Grant/Award
3 txns
Insider
Pamukcu Rifat
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (Right to Buy) | 12,555 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 3,135 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Options (Right to Buy) — 12,555 contracts (Direct);
Common Stock — 8,581 shares (Direct);
Common Stock — 14,108 shares (Indirect, By ZNZ Holdings LLC)
Footnotes (3)
- F1. These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
- F2. The Reporting Person serves as Manager Partner of ZNZ Holdings L.L.C.
- F3. The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
Key Figures
Restricted stock units granted: 3,135 units
Stock options granted: 12,555 options
Option exercise price: $0.7293 per share
+3 more
6 metrics
Restricted stock units granted
3,135 units
Granted on June 16, 2026; vest June 16, 2027
Stock options granted
12,555 options
Granted on June 16, 2026; expire June 16, 2036
Option exercise price
$0.7293 per share
Stock options on common stock
Direct common shares after awards
8,581 shares
Total direct holdings following transactions
Indirect common shares via ZNZ Holdings
14,108 shares
Indirect holdings reported as by ZNZ Holdings LLC
Option expiration date
June 16, 2036
Expiration of 12,555 granted stock options
Key Terms
restricted stock units, Stock Options (Right to Buy), indirect ownership, Grant, award, or other acquisition, +1 more
5 terms
restricted stock units financial
"These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Options (Right to Buy) financial
"Stock Options (Right to Buy) with 12,555.0000 shares and an exercise price of 0.7293"
indirect ownership financial
"total_shares_following_transaction 14108.0000 with ownership_type indirect and nature_of_ownership By ZNZ Holdings LLC"
Grant, award, or other acquisition financial
"transaction_code_description Grant, award, or other acquisition for the common stock and option grants"
vesting financial
"which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Aprea Therapeutics (APRE) director Rifat Pamukcu receive?
Rifat Pamukcu received 3,135 restricted stock units and stock options for 12,555 shares. Both awards were granted on June 16, 2026 and are tied to his continued service on Aprea Therapeutics’ board, with vesting dates in June 2027.
When do the new Aprea Therapeutics (APRE) RSUs for Rifat Pamukcu vest?
The 3,135 restricted stock units vest and settle in common stock on June 16, 2027. Vesting requires Pamukcu’s continued service on Aprea Therapeutics’ board through that date and may accelerate under certain specified conditions in the award terms.
What are the key terms of Rifat Pamukcu’s new Aprea Therapeutics stock options?
Pamukcu’s new options cover 12,555 shares of common stock at an exercise price of $0.7293 per share. The options vest in full on June 16, 2027, conditioned on his continued board service and subject to potential acceleration provisions.
What is the nature of Rifat Pamukcu’s indirect ownership in Aprea Therapeutics?
Pamukcu’s indirect ownership consists of 14,108 Aprea Therapeutics common shares held by ZNZ Holdings LLC. The filing notes he serves as Manager Partner of ZNZ Holdings, indicating these shares are held through that entity rather than in his personal name.
AI-generated analysis. How Rhea-AI works. Not financial advice.
